Methylphenidate for ADHD rejected from the WHO Essential Medicines List due to uncertainties in benefit-harm profile | BMJ Evidence-Based Medicine

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

EBM analysis

Mental health

Methylphenidate for ADHD rejected from the WHO Essential Medicines List due to uncertainties in benefit-harm profile

Online download statistics by month:

Online download statistics by month: April 2020 to May 2023

	Abstract	Full	Pdf
Apr 2020	744	38	21
May 2020	1484	53	26
Jun 2020	1916	17	8
Jul 2020	2013	11	7
Aug 2020	629	14	6
Sep 2020	335	8	2
Oct 2020	224	7	5
Nov 2020	1369	9	6
Dec 2020	410	4	6
Jan 2021	191	12	6
Feb 2021	189	11	15
Mar 2021	185	9	5
Apr 2021	337	3	1
May 2021	334	3	1
Jun 2021	4	1	0
Jul 2021	27	15	9
Aug 2021	44	25	17
Sep 2021	30	12	8
Oct 2021	442	25	20
Nov 2021	564	28	6
Dec 2021	772	11	6
Jan 2022	330	11	2
Feb 2022	186	7	3
Mar 2022	276	8	5
Apr 2022	223	11	6
May 2022	244	10	1
Jun 2022	256	11	6
Jul 2022	175	5	4
Aug 2022	161	7	1
Sep 2022	180	8	2
Oct 2022	225	7	6
Nov 2022	152	16	2
Dec 2022	103	16	8
Jan 2023	206	2	1
Feb 2023	139	2	1
Mar 2023	166	4	4
Apr 2023	215	2	0
May 2023	135	4	1
Total	15615	447	234